Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants

References

• Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7:439–450.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181:894–904.e9.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281–292.e6.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–224.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8.
   PubMed Web of Science ®Google Scholar
• Tang T, Bidon M, Jaimes JA, et al. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res. 2020;178:104792.
   PubMed Web of Science ®Google Scholar
• Wang X, Xia S, Wang Q, et al. Broad-spectrum coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus diseases. Int J Mol Sci. 2020;21:3843.
   PubMed Web of Science ®Google Scholar
• He Y. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion. Curr Pharm Des. 2013;19:1800–1809.
   PubMed Web of Science ®Google Scholar
• Liu S, Xiao G, Chen Y, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363:938–947.
   PubMed Web of Science ®Google Scholar
• Bosch BJ, Martina BE, Van Der Zee R, et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci USA. 2004;101:8455–8460.
   PubMed Web of Science ®Google Scholar
• Lu L, Liu Q, Zhu Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
   PubMed Web of Science ®Google Scholar
• Xia S, Yan L, Xu W, et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019;5:eaav4580.
   PubMed Web of Science ®Google Scholar
• Ujike M, Nishikawa H, Otaka A, et al. Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. J Virol. 2008;82:588–592.
   Web of Science ®Google Scholar
• Porotto M, Yokoyama CC, Palermo LM, et al. Viral entry inhibitors targeted to the membrane site of action. J Virol. 2010;84:6760–6768.
   PubMed Web of Science ®Google Scholar
• Porotto M, Rockx B, Yokoyama CC, et al. Inhibition of nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog. 2010;6:e1001168.
   Web of Science ®Google Scholar
• Ingallinella P, Bianchi E, Ladwa NA, et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci USA. 2009;106:5801–5806.
   Web of Science ®Google Scholar
• Ashkenazi A, Viard M, Unger L, et al. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1. FASEB J. 2012;26:4628–4636.
   Web of Science ®Google Scholar
• Chong H, Wu X, Su Y, et al. Development of potent and long-acting HIV-1 fusion inhibitors. AIDS. 2016;30:1187–1196.
   PubMed Web of Science ®Google Scholar
• Lee KK, Pessi A, Gui L, et al. Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J Biol Chem. 2011;286:42141–42149.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Chong H, Yu D, et al. Design and characterization of cholesterylated peptide HIV-1/2 fusion inhibitors with Extremely Potent and long-lasting antiviral activity. J Virol. 2019;93:e02312–e02318.
   Web of Science ®Google Scholar
• Chong H, Xue J, Zhu Y, et al. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathog. 2019;15:e1007552.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang X, Ding X, et al. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. J Biol Chem. 2018;293:5323–5334.
   PubMed Web of Science ®Google Scholar
• Chong H, Zhu Y, Yu D, et al. Structural and functional characterization of Membrane Fusion Inhibitors with Extremely Potent activity against HIV-1, HIV-2, and simian immunodeficiency virus. J Virol. 2018;92:e01088–e01018.
   Web of Science ®Google Scholar
• Chong H, Xue J, Zhu Y, et al. Design of novel HIV-1/2 fusion inhibitors with high therapeutic efficacy in rhesus monkey models. J Virol. 2018;92:e00775–e00718.
   Web of Science ®Google Scholar
• Ding X, Zhang X, Chong H, et al. Enfuvirtide (T20)-based lipopeptide Is a potent HIV-1 cell fusion inhibitor: implication for viral entry and inhibition. J Virol. 2017;91:e00831–e00817.
   Web of Science ®Google Scholar
• Chong H, Xue J, Xiong S, et al. A lipopeptide HIV-1/2 fusion inhibitor with highly potent In Vitro, Ex Vivo, and In vivo antiviral activity. J Virol. 2017;91:e00288–e00217.
   Web of Science ®Google Scholar
• Zhu Y, Yu D, Yan H, et al. Design of potent membrane fusion inhibitors against SARS-CoV-2, an Emerging Coronavirus with high fusogenic activity. J Virol. 2020;94:e00635–e00620.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yu D, Hu Y, et al. SARS-CoV-2 derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther. 2021. In the press.
   Web of Science ®Google Scholar
• Outlaw VK, Bovier FT, Mears MC, et al. Inhibition of coronavirus entry In Vitro and Ex Vivo by a lipid-conjugated peptide derived from the SARS-CoV-2 spike glycoprotein HRC domain. mBio. 2020;11: e01935-20.
   Web of Science ®Google Scholar
• Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020;30:343–355.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812–827.e19.
   PubMed Web of Science ®Google Scholar
• Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592:116–121.
   PubMed Web of Science ®Google Scholar
• Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27:917–924.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.
   PubMed Web of Science ®Google Scholar
• Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–119.
   PubMed Web of Science ®Google Scholar
• Kaptein SJF, Jacobs S, Langendries L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci USA. 2020;117:26955–26965.
   PubMed Web of Science ®Google Scholar
• Saha RP, Sharma AR, Singh MK, et al. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Front Pharmacol. 2020;11:1258.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517–525.
   PubMed Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382:2327–2336.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578.
   PubMed Web of Science ®Google Scholar
• Hassaniazad M, Bazram A, Hassanipour S, et al. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21:886.
   Web of Science ®Google Scholar
• Zhu Y, Yu D, Han Y, et al. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Sci Adv. 2020;6:eabc9999.
   PubMed Web of Science ®Google Scholar
• Tai W, Zhang X, He Y, et al. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020;179:104820.
   PubMed Web of Science ®Google Scholar
• Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. 2020;369:1603–1607.
   PubMed Web of Science ®Google Scholar
• Yu D, Zhu Y, Yan H, et al. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 2021;10:810–821.
   PubMed Web of Science ®Google Scholar
• Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA. 2005;102:11876–11881.
   PubMed Web of Science ®Google Scholar
• Iwata-Yoshikawa N, Okamura T, Shimizu Y, et al. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol. 2019;93:e01815–e01818.
   PubMed Web of Science ®Google Scholar
• Kawase M, Shirato K, van der Hoek L, et al. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86:6537–6545.
   PubMed Web of Science ®Google Scholar
• Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85:4122–4134.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78:779–784.e5.
   PubMed Web of Science ®Google Scholar
• Park JE, Li K, Barlan A, et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci USA. 2016;113:12262–12267.
   PubMed Web of Science ®Google Scholar
• Kleine-Weber H, Elzayat MT, Hoffmann M, et al. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Sci Rep. 2018;8:16597.
   PubMed Web of Science ®Google Scholar
• Figueira TN, Augusto MT, Rybkina K, et al. Effective in vivo targeting of influenza virus through a cell-penetrating/fusion inhibitor tandem peptide anchored to the plasma membrane. Bioconjug Chem. 2018;29:3362–3376.
   Web of Science ®Google Scholar
• de Vries RD, Schmitz KS, Bovier FT, et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science. 2021;371:1379–1382.
   PubMed Web of Science ®Google Scholar